A persistent, often progressive, lung disease, COPD results from chronic inflammation that leads to structural changes ...

as an add-on maintenance treatment for adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and ...

Regeneron spent $5 billion repurchasing shares from Sanofi in May 2020 and $900 million repurchasing global rights to Libtayo in July 2022, yet a windfall from sales of its covid antibody cocktail as ...

Dupixent, a Sanofi and Regeneron Pharmaceuticals drug, is now approved for chronic obstructive pulmonary disease (COPD), a progressive lung disease prevalent in smokers. It’s the sixth FDA ...

Its growth is attributed to the introduction of new treatments. The chronic obstructive pulmonary disease (COPD) market is ...

Despite disappointing third-quarter results for Regeneron’s high-dose Eylea injection, analysts continued to be cautiously ...

Regeneron should weather the Eylea biosimilar launch storm and continue to deliver long-term shareholder value. See why REGN ...

Advertiser: Sanofi and Regeneron In the United States, more than 10 million people above the age of 40 live with chronic obstructive pulmonary disease (COPD), a chronic lung disease that limits ...

and chronic obstructive pulmonary disease in different age populations. More than 1,000,000 patients are being treated with Dupixent globally. Dupilumab is being jointly developed by Regeneron and ...

and chronic obstructive pulmonary disease in different age populations. More than 1,000,000 patients are being treated with Dupixent globally. Dupilumab is being jointly developed by Regeneron and ...